NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Athenex, Inc. ATNX between August 7, 2019 and February 26, 2021, inclusive (the "Class Period").
To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=athenex-inc&id=2652 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.
如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=athenex-inc&id=2652
If you wish to serve as lead plaintiff, you must move the Court before the May 3, 2021 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- the data included in the Oral Paclitaxel and Encequidar New Drug Application ("NDA") presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; the uncertainty over the results of the primary endpoint of objective response rate ("ORR") at week 19 conducted by blinded independent central review ("BICR"); the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.
Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.
Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
info@zhanginvestorlaw.com
tel: (800) 991-3756
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
